Cerecor acquired worldwide, exclusive rights to develop and commercialize the Merck & Co compound MK-0657 (now CERC-301) – a small molecule NMDA receptor subunit 2 (NR2B) antagonist – in all indications, including depression. It is the first oral drug in the well-populated class of drugs targeting the NMDA receptor and the first oral rapid-acting antidepressant.
The news in a nutshell
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?